# LIBERTAS (NCT05884398)

> A Study of an Intermittent ADT Approach With Apalutamide Monotherapy in Participants With mCSPC

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05884398
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Janssen Research & Development, LLC
- Conditions: Metastatic Castrate-sensitive Prostate Cancer
- Interventions: Apalutamide; Androgen-deprivation Therapy (ADT)
- Enrollment: 420
- Primary outcome: Percentage of Participants With 18-Months Radiographic Progression-free Survival (rPFS)
- Primary outcome: Percent Change From Randomization in Severity of Adjusted Hot Flash Score at 18 Months

## Commentary we found

- X threads: 21
- YouTube: 10
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=libertas-nct05884398

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05884398", "email": "<work email>"}; the inbox owner confirms by the emailed link.